08 September, 2010

Hypoglycemic agents - Extinct, Present & Future

Sensitizers

Biguanides -Metformin, Buformin ( withdrawn from market),Phenformin ( withdrawn from market)
TZDs (PPAR) - Pioglitazone, Rivoglitazone ( in clinical trials), Rosiglitazone ( about to be withdrawn from market), Troglitazone ( withdrawn from market)
Dual PPAR agonists - Aleglitazar ( in clinical trials), Muraglitazar ( dropped during clinical trials), Tesaglitazar ( dropped during clinical trials)

Secretagogues

Sulfonylureas - 1st generation: Acetohexamide, Carbutamide, Chlorpropamide ,Gliclazide, Tolbutamide, Tolazamide.
2nd generation: Glibenclamide (Glyburide),Glipizide, Gliquidone, Glyclopyramide
3rd generation: Glimepiride

Meglitinides/"glinides" - Nateglinide, Repaglinide, Mitiglinide

GLP-1 analogs -Exenatide, Liraglutide, Taspoglutide( in clinical trials), Albiglutide ( in clinical trials)

DPP-4 inhibitors - Alogliptin ( in clinical trials), Linagliptin( in clinical trials), Saxagliptin, Sitagliptin, Vildagliptin

Analogs/other insulins -
Fast acting (Insulin lispro, Insulin aspart, Insulin glulisine)
Short acting (Regular insulin)
Long acting (Insulin glargine , Insulin detemir)
Inhalable insulin (Exubera)- withdrawn from market
NPH insulin

Alpha-glucosidase inhibitors -Acarbose, Miglitol , Voglibose

Amylin analog - Pramlintide

SGLT2 inhibitors - Canagliflozin ( in clinical trials) , Dapagliflozin ( in clinical trials) , Remogliflozin( in clinical trials) , Sergliflozin( in clinical trials)

Others - Benfluorex , Tolrestat ( withdrawn from market)

1 comment :

  1. Good. I think all covered.Now a days the term OHA is not used, as all the agents doesnot cause hypoglycemia. Anti hyperglycemic agent or, Oral Anti Diabetic agents are the recent terms.

    ReplyDelete

Feel free to Comment!!

ShareThis